Diplomat Dispensing REVLIMID® for Multiple Myeloma Maintenance Therapy Following Autologous Hematopoietic Stem Cell Transplant (Auto-HSCT)

03/02/2017

The nation's largest independent specialty pharmacy is dispensing the newly expanded indication of limited-distribution drug REVLIMID® (lenalidomide).

FLINT, Mich., March 2, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is filling prescriptions for REVLIMID® (lenalidomide) for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). This is an expanded indication for REVLIMID® recently approved by the Food and Drug Administration.

To learn more about Diplomat's oncology program, visit diplomat.is/areas-of-excellence/oncology.

"Diplomat has been distributing REVLIMID®, which is only available through a Risk Evaluation and Mitigation Strategy (REMS), since 2006," said Paul Urick, Diplomat's president. "Our distribution of the product is just one of the ways Diplomat is supporting the delivery of comprehensive care."

Multiple myeloma is a hematological (blood) cancer in which malignant plasma cells form in the bone marrow, producing abnormal proteins. According to the American Cancer Society, about 30,280 Americans will be diagnosed with multiple myeloma in 2017.

REVLIMID® is manufactured by Celgene Corporation. For full prescribing information, click here.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2015, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomat-dispensing-revlimid-for-multiple-myeloma-maintenance-therapy-following-autologous-hematopoietic-stem-cell-transplant-auto-hsct-300416870.html

SOURCE Diplomat Pharmacy, Inc.

Kali Lucas, Public Relations Specialist, 810.768.9580, press@diplomat.is; Gary Rice, RPh, MS, MBA, CSP, Executive Vice President of Operations, 810.768.9863, grice@diplomat.is

NYSE: DPLO

+0.07 +0.45% $ 15.63 Volume: 715,199 Common Stock | 20 minute delay July 21, 2017

Investor Contact

Asher S. Dewhurst

Investor Relations,
Westwicke Partners, LLC.
diplomat@westwicke.com

Phone: 443.213.0500

Email Now